Literature DB >> 9872549

Calcitonin-producing pancreatic somatostatinoma: report of a case.

F Sugimoto1, T Sekiya, M Saito, T Iiai, K Suda, A Nozawa, T Nakazawa, T Ishizaki, T Ikarashi.   

Abstract

A 59-year-old woman was hospitalized due to a 1-year history of diarrhea and weight loss. Echography and computed tomography of the abdomen revealed a 10 x 7 cm solid mass in the tail of the pancreas and gallstones, while selective celiac angiography revealed the presence of a hypervascular mass. High levels of somatostatin and calcitonin were detected in the plasma, 70 pg/ml (normal range <28 pg/ml) and 5550 pg/ml (normal range 37 +/- 8 pg/ml), respectively. This tumor was thus removed by means of a distal pancreatectomy and a splenectomy. After the pancreatic tumor was removed, the elevated levels of plasma somatostatin and calcitonin returned to the normal ranges, and the persistent diarrhea also dramatically disappeared. A postoperative immunohistochemical study showed the tumor cells to be diffusely positive for somatostatin and calcitonin. These results clearly indicate this patient to be a case of calcitonin-producing pancreatic somatostatinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9872549     DOI: 10.1007/BF02482815

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  8 in total

1.  Malignant islet cell tumor of the pancreas associated with high plasma calcitonin and somatostatin levels.

Authors:  J M Howard; A F Gohara; R J Cardwell
Journal:  Surgery       Date:  1989-02       Impact factor: 3.982

2.  Pancreatic islet cell carcinoma producing gastrin, ACTH, alpha-endorphin, somatostatin and calcitonin.

Authors:  S L Asa; K Kovacs; D W Killinger; N Marcon; M Platts
Journal:  Am J Gastroenterol       Date:  1980-07       Impact factor: 10.864

3.  Molecular forms of somatostatin in normal subjects and in patients with pancreatic somatostatinoma.

Authors:  E Penman; P J Lowry; J A Wass; V Marks; A M Dawson; G M Besser; L H Rees
Journal:  Clin Endocrinol (Oxf)       Date:  1980-06       Impact factor: 3.478

4.  Calcitonin secretion by a pancreatic somatostatinoma.

Authors:  J P Galmiche; R Colin; P M DuBois; J A Chayvialle; F Descos; C Paulin; Y Geffroy
Journal:  N Engl J Med       Date:  1978-11-30       Impact factor: 91.245

5.  Somatostatinoma syndrome. Biochemical, morphologic and clinical features.

Authors:  G J Krejs; L Orci; J M Conlon; M Ravazzola; G R Davis; P Raskin; S M Collins; D M McCarthy; D Baetens; A Rubenstein; T A Aldor; R H Unger
Journal:  N Engl J Med       Date:  1979-08-09       Impact factor: 91.245

6.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728

7.  Pancreatic somatostatinoma. Clinical features and physiological implications.

Authors:  L I Larsson; M A Hirsch; J J Holst; S Ingemansson; C Kühl; S L Jensen; G Lundqvist; J F Rehfeld; T W Schwartz
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

Review 8.  Pancreatic somatostatinoma: a case report and review of the literature.

Authors:  K Konomi; K Chijiiwa; T Katsuta; K Yamaguchi
Journal:  J Surg Oncol       Date:  1990-04       Impact factor: 3.454

  8 in total
  2 in total

Review 1.  Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas: Clinicopathological Study of 25 Cases and Review of the Literature.

Authors:  Silvia Uccella; Annika Blank; Roberta Maragliano; Fausto Sessa; Aurel Perren; Stefano La Rosa
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

2.  Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Eleni Papoutsi; Vasiliki Ntella; Prodromos Kanavidis; Athanasios Sioulas; Marina Tsoli; Georgios Charalampopoulos; Michail Vailas; Evangelos Felekouras
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.